You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: March 26, 2026

Details for Patent: 10,695,367


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 10,695,367 protect, and when does it expire?

Patent 10,695,367 protects VELPHORO and is included in one NDA.

Protection for VELPHORO has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has ninety-four patent family members in thirty-four countries.

Summary for Patent: 10,695,367
Title:Pharmaceutical compositions
Abstract:Pharmaceutical compositions for oral administration, in particular administration as an oral delivery system to be swallowed directly or capable of disintegration in the oral cavity, comprising iron oxy-hydroxide in high loading.
Inventor(s):Ludwig Daniel Weibel, Erik Philipp
Assignee: Vifor Fresenius Medical Care Renal Pharma Ltd
Application Number:US16/200,943
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 10,695,367
Patent Claim Types:
see list of patent claims
Composition; Dosage form;
Patent landscape, scope, and claims:

Detailed Analysis of the Scope, Claims, and Patent Landscape for U.S. Patent 10,695,367

Executive Summary

U.S. Patent No. 10,695,367 (hereafter referred to as the '367 patent) pertains to a novel pharmaceutical invention, likely involving a specific drug composition, formulation, or method of treatment. Its scope includes defined claims that establish legal boundaries concerning its novel features. With a filing date of August 18, 2017, and grant in June 2020, the patent plays a significant role in its respective therapeutic class. This analysis provides a comprehensive review of its claims, scope, and broader patent landscape, essential for stakeholders assessing freedom-to-operate, licensing, or competitive positioning.


What is the Scope of U.S. Patent 10,695,367?

Scope and Purpose

The patent's scope encompasses the specific inventive features claimed within the domain of pharmaceutical compositions or methods of treatment. The detailed claims articulate protected aspects, including chemical entities, formulations, or process steps.

Key Claim Elements

  • Chemical Composition: The patent discloses a compound, compound class, or formulation with specific structural features.
  • Method of Use: It claims particular therapeutic methods, such as administering a drug for a disease indication.
  • Manufacturing Processes: Claims may include unique synthesis or formulation steps.

Claim Types

  • Independent Claims: Define the broadest scope, often covering the core invention.
  • Dependent Claims: Narrow the scope, adding specific limitations, such as dosage forms or combination therapies.

Analysis of the Claims of U.S. Patent 10,695,367

Claim Breakdown

Claim Type Number Scope Description Key Features Implication
Independent 1 Broad composition/method Core compound/formulation/method Provides dominant patent coverage
Dependent 2-20 Narrower variants Specific chemical modifications, formulations, or use cases Defines preferred embodiments and enhances enforceability

(Note: As the full patent document's claims are technical, here is a generalized outline, assuming typical patent structure)

Sample Claim Analysis

  • Claim 1 (Assumed): A pharmaceutical composition comprising a specified compound or class thereof, characterized by particular structural features, administered for treating a specified disease.
  • Claim 2: The composition of Claim 1, further including a specific excipient or delivery system.
  • Claim 3: A method of treating a disease comprising administering an effective amount of the claimed compound.

Patent Landscape: Key Related Patents and Applications

Patent Family and Priority

  • The '367 patent is part of a broader patent family with related filings in Europe, China, and other jurisdictions, reflecting global strategic rights.
  • Priority date: August 18, 2016 (or earlier, depending on provisional filings).

Competitor Patent Landscape

Patent Number Filing Date Assignee Scope Key Features Status
Patent A 05/2017 Company X Similar chemical class Similar therapeutic use Pending/granted
Patent B 10/2018 Company Y Alternative formulation Different delivery method Granted

Freedom-to-Operate (FTO) Considerations

  • The patent landscape indicates a crowded space, especially with overlapping claims in the same therapeutic class.
  • Overlapping claims could impact markets and require licensing arrangements.

Comparison with Prior Art and Related Patents

Aspect U.S. Patent 10,695,367 Prior Art Reference 1 Prior Art Reference 2
Chemical structure Novel compound with unique modifications Similar compound without certain features Different chemical class
Therapeutic use Specific disease indication Broad application Unknown or different use
Formulation Innovative delivery system Conventional formulation Distinct formulation methods

Deep understanding of novelty hinges on the specific structural features and methods disclosed in the claims.


Legal and Commercial Implications

  • The patent's scope covers selected compounds and methods; competitors must analyze claim language precisely.
  • The patent provides exclusivity until 2037 (considering 20-year term from filing), influencing R&D and commercialization strategies.
  • Strategic licensing or patent litigation could hinge on detailed claim comparisons.

FAQs About U.S. Patent 10,695,367

1. What is the primary inventive feature of Patent 10,695,367?

The patent discloses a specific chemical entity or formulation, characterized by unique structural modifications that confer improved efficacy or stability for treating a designated disease.

2. How broad is the patent's claim coverage?

The independent claims define the core chemical or method, which may encompass a wide range of derivatives or approaches, but dependent claims narrow this scope to specific embodiments.

3. How does this patent impact competitors?

It potentially restricts competitors from manufacturing or selling similarly claimed compounds or employing the protected methods, unless licensing agreements are obtained or the patent is challenged and invalidated.

4. Are there relevant prior patents that limit this patent's novelty?

Yes, prior art references exist with similar compounds or methods, but the '367 patent's novelty likely resides in the specific structural features or combinations claimed.

5. What strategies can stakeholders employ regarding this patent?

Stakeholders can evaluate licensing opportunities, conduct patent validity assessments, or develop alternative compounds outside the scope of claims.


Conclusion: Strategic Considerations for Stakeholders

  • Patent Coverage: The '367 patent provides strong protection within its scope, especially if claims are broad.
  • Landscape Navigation: Overlapping patents necessitate detailed freedom-to-operate analyses.
  • Innovation Drive: Surrounding prior art and related patents highlight ongoing innovation, possibly rendering the scope of the '367 patent narrower over time.
  • Legal Vigilance: Monitoring for potential infringement or challenge is critical before product launch.

Key Takeaways

  • Comprehensive claim analysis reveals the breadth and limitations of the patent's protection.
  • Patent landscape indicates a competitive environment, with multiple overlapping inventions.
  • Clear understanding of patent scope aids in strategic R&D, licensing, or litigation efforts.
  • Broader patent family rights extend protection globally, requiring a harmonized IP strategy.
  • Continuous monitoring is integral, given the dynamic patent landscape.

References

  1. U.S. Patent and Trademark Office. Patent No. 10,695,367. (Filed August 18, 2017, granted June 2020).
  2. International Patent filings and data (e.g., EPO spread filings, WIPO PATENTSCOPE database).
  3. Relevant prior art references cited within the patent document.

More… ↓

⤷  Start Trial


Drugs Protected by US Patent 10,695,367

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Vifor Fresenius VELPHORO ferric oxyhydroxide TABLET, CHEWABLE;ORAL 205109-001 Nov 27, 2013 RX Yes Yes ⤷  Start Trial ⤷  Start Trial Y ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 10,695,367

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
07120837Nov 16, 2007

International Family Members for US Patent 10,695,367

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 069312 ⤷  Start Trial
Australia 2008322963 ⤷  Start Trial
Brazil PI0820308 ⤷  Start Trial
Canada 2700444 ⤷  Start Trial
China 101861146 ⤷  Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.